Head-To-Head Contrast: Tenaya Therapeutics (NASDAQ:TNYA) vs. Pharming Group (OTCMKTS:PHGUF)

Tenaya Therapeutics (NASDAQ:TNYA) and Pharming Group (OTCMKTS:PHGUF) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tenaya Therapeutics and Pharming Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1	0	5	1	2.86
Pharming Group	0	0	0	0	0.00

Tenaya Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 474.55%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Pharming Group.

Profitability

This table compares Tenaya Therapeutics and Pharming Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Pharming Group	2.51%	3.40%	1.88%

Volatility & Risk

Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tenaya Therapeutics and Pharming Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60 million	($0.53)	-1.31
Pharming Group	$376.13 million	1.96	$2.85 million	$0.01	110.00

Pharming Group has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

90.5% of Tenaya Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.